Clinical Trial to Evaluate the Efficacy and Safety of DP-R212

• Status: Withdrawn
• Trial end date: 2017-08-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine superiority of DP-R212 comparing to each monotherapy in patient with hypertension and primary hypercholesterolemia.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Alvogen Korea

Criteria

Inclusion Criteria:

• Both man and woman who is over 19 years old

• Hypertension patient with hypercholesterolemia

Exclusion Criteria:

• sSBP difference is ≥20mmHg or sDBP difference is ≥10mmHg

• A history of cardiovascular disease

• rhabdomyolysis, myopathy

• Hypertension or hypercholesterolemia due to secondary causes

• Uncontrolled diabetes

• Evidence of hepatic or renal disease